Translate Bio Inc (NASDAQ:TBIO) shares saw an uptick in trading volume on Friday . 1,378,700 shares were traded during trading, an increase of 538% from the previous session’s volume of 216,146 shares.The stock last traded at $8.13 and had previously closed at $7.94.
A number of research firms have recently weighed in on TBIO. Zacks Investment Research raised shares of Translate Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Roth Capital began coverage on shares of Translate Bio in a research report on Tuesday, June 18th. They set a “buy” rating and a $25.00 price target for the company. Jefferies Financial Group began coverage on shares of Translate Bio in a research report on Monday, July 22nd. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Translate Bio in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Translate Bio presently has a consensus rating of “Buy” and a consensus target price of $22.75.
The company has a debt-to-equity ratio of 1.15, a quick ratio of 7.67 and a current ratio of 7.67. The business’s 50-day moving average price is $9.54 and its two-hundred day moving average price is $9.63.
Translate Bio (NASDAQ:TBIO) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.73 million. Translate Bio had a negative return on equity of 84.22% and a negative net margin of 2,696.98%. Research analysts expect that Translate Bio Inc will post -1.96 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new position in Translate Bio in the second quarter worth $31,000. Wells Fargo & Company MN boosted its holdings in Translate Bio by 30.5% in the second quarter. Wells Fargo & Company MN now owns 14,532 shares of the company’s stock worth $183,000 after purchasing an additional 3,393 shares during the period. Bank of New York Mellon Corp boosted its holdings in Translate Bio by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 85,689 shares of the company’s stock worth $1,083,000 after purchasing an additional 5,544 shares during the period. Aevitas Wealth Management Inc. acquired a new position in Translate Bio in the first quarter worth $58,000. Finally, BNP Paribas Arbitrage SA acquired a new position in Translate Bio in the first quarter worth $63,000. 57.90% of the stock is owned by hedge funds and other institutional investors.
About Translate Bio (NASDAQ:TBIO)
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
See Also: The primary rules of Elliott Wave theory
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.